Decision/Risk Analysis · Boston, MA · Founded 2019 · Privately Held (backing)
Developer of a cell surface scanning platform designed to assist oncologists in performing noninvasive detection of bladder cancer. Cellens is based in Boston, MA and was founded in 2019. It was valued at $19.4 million at its early-stage round in Aug 2025, the last priced event on record. It has raised $7.5 million across 3 recorded rounds; the latest was a $6.4 million early-stage round in Aug 2025.
PMV mark · valuation
$19.4M
Oct 2026
Priced at
its early-stage round
Aug 2025
Total raised
$7.5M
Last round
Early Stage VC
Aug 2025
Team — not yet on record
No current team members for Cellens are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Cellens with a free account
·The complete investor list: 19 names
·Watch Cellens: the Monday email on marks, rounds and moves
